Trial record 1 of 1 for: 01267227

Previous Study | Return to List | Next Study

Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Daniel Riche, University of Mississippi Medical Center

ClinicalTrials.gov Identifier:

NCT01267227

First received: December 17, 2010

Last updated: May 2, 2013

Last verified: May 2013

History of Changes

Results First Received: March 19, 2013

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor); Primary Purpose: Treatment
Conditions:	Hyperlipidemia Blood Pressure Oxidative Stress
Interventions:	Drug: Pterostilbene 50 mg twice daily Drug: Placebo Drug: Grape Extract Drug: Pterostilbene 125 mg twice daily

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Medical clinic

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
High Dose	Pterostilbene 125 mg twice daily
Low Dose	Pterostilbene 50 mg twice daily
Low Dose Combination	Pterostilbene 50 mg/Grape Extract 100 mg twice daily
Placebo	Matching placebo twice daily

Participant Flow: Overall Study

	High Dose	Low Dose	Low Dose Combination	Placebo
STARTED	20	20	20	20
COMPLETED	19	19	18	17
NOT COMPLETED	1	1	2	3

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
High Dose	Pterostilbene 125 mg twice daily
Low Dose	Pterostilbene 50 mg twice daily
Low Dose Combination	Pterostilbene 50 mg/Grape Extract 100 mg twice daily
Placebo	Matching placebo twice daily
Total	Total of all reporting groups

Baseline Measures

	High Dose	Low Dose	Low Dose Combination	Placebo	Total
Number of Participants [units: participants]	20	20	20	20	80
Age [units: participants]
<=18 years	0	0	0	0	0
Between 18 and 65 years	16	19	17	17	69
>=65 years	4	1	3	3	11
Age [units: years] Mean ± Standard Deviation	53.6 ± 11.2	53.6 ± 7.9	53.0 ± 13.7	54.4 ± 11.9	53.6 ± 11.2
Gender [units: participants]
Female	14	15	15	13	57
Male	6	5	5	7	23
Region of Enrollment [units: participants]
United States	20	20	20	20	80

Outcome Measures

Show All Outcome Measures

1. Primary:

Triglycerides [ Time Frame: Baseline and 6-8 weeks ]

Show Outcome Measure 1

2. Secondary:

Subjective Adverse Effects [ Time Frame: Baseline and 6-8 weeks ]

Show Outcome Measure 2

3. Secondary:

Blood Pressure [ Time Frame: 6-8 weeks ]

Results not yet posted. Anticipated Posting Date: No text entered. Safety Issue: No

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: Disclosure of the submitted materials approved per contractual agreement.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Dr. Daniel Riche
Organization: University of Mississippi
phone: 601-984-2640
e-mail: driche@umc.edu

Publications of Results:

Paul S, Rimando AM, Lee HJ, Ji Y, Reddy BS, Suh N. Anti-inflammatory action of pterostilbene is mediated through the p38 mitogen-activated protein kinase pathway in colon cancer cells. Cancer Prev Res (Phila). 2009 Jul;2(7):650-7. Epub 2009 Jun 23.

Rimando AM, Kalt W, Magee JB, Dewey J, Ballington JR. Resveratrol, pterostilbene, and piceatannol in vaccinium berries. J Agric Food Chem. 2004 Jul 28;52(15):4713-9.

Rimando AM, Nagmani R, Feller DR, Yokoyama W. Pterostilbene, a new agonist for the peroxisome proliferator-activated receptor alpha-isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. J Agric Food Chem. 2005 May 4;53(9):3403-7.

Amarnath Satheesh M, Pari L. The antioxidant role of pterostilbene in streptozotocin-nicotinamide-induced type 2 diabetes mellitus in Wistar rats. J Pharm Pharmacol. 2006 Nov;58(11):1483-90.

Satheesh AM, Pari L. Effect of pterostilbene on lipids and lipid profiles in streptozotocin-nicotinamide induced type 2 diabetes mellitus. Journal of Applied Biomedine 6(1):31-37, 2008.

Responsible Party:	Daniel Riche, University of Mississippi Medical Center
ClinicalTrials.gov Identifier:	NCT01267227 History of Changes
Other Study ID Numbers:	2010-0225
Study First Received:	December 17, 2010
Results First Received:	March 19, 2013
Last Updated:	May 2, 2013
Health Authority:	United States: Institutional Review Board

To Top